LICENSE AGREEMENT BY AND BETWEEN IMMUNOMEDICS, INC. AND EVEREST MEDICINES II LIMITED DATED AS OF APRIL 28TH, 2019License Agreement • August 7th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
THIS LICENSE AGREEMENT (the “Agreement”) is effective as of April 28th, 2019 (the “Effective Date”), by and between IMMUNOMEDICS, INC., a Delaware corporation having its principal place of business at 300 The American Road, Morris Plains, New Jersey 07950, U.S.A. (“Company”), and EVEREST MEDICINES II LIMITED, an exempted company organized and existing under the laws of Cayman Islands, having its principal place of business at Room 3306-3307, Two Exchange Square, 8 Connaught, Hong Kong (“Licensee”). Company and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PROMOTION AGREEMENT by and between JANSSEN BIOTECH, INC. and IMMUNOMEDICS, INC. Dated as of: April 5, 2019Promotion Agreement • August 7th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This PROMOTION AGREEMENT (this “Agreement”) dated as of April 5, 2019 (the “Effective Date”), is entered into by and between Janssen Biotech, Inc., a corporation organized under the laws of Pennsylvania (“Janssen”) and Immunomedics, Inc., a corporation organized under the laws of Delaware (“Company”).
CONSULTING AGREEMENTConsulting Agreement • August 7th, 2019 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
CONSULTING AGREEMENT, dated as of May 28, 2019, by and between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the "Company"), and Robert Iannone ("Consultant") (each, a "Party"; together, the "Parties"):
